Ankur Drugs and Pharma has received an approval to raise upto Rs 140 crore by issuing following instruments. The company will raise upto Rs 100.00 crore by way of Non Convertible Warrants and it will also raise upto another Rs 40.00 crore by way of Share Warrants. The company has received an approval at its board meeting held on August 12, 2011.
Recently, Ankur Drugs and Pharma had set up a state of the art facilities in tax free zone at Baddi in Himachal Pradesh. In order to avail the concessions under the Industrial Package announced by the Central Government for the state of Himachal Pradesh the project was slated to be completed on or before March 31, 2010. Due to this the company could not tie up the long term finds and it was forced to raise funds from all available resources for completing the project. The project was technically completed making the company eligible for concessions but it ended up in mismatch of long term and short term resources.
Ankur Drugs and Pharma, formerly the Mridol Pharmaceuticals, was incorporated on February 9, 1995. Currently Ankur manufactures 400 different formulations for different dosage forms - viz tablets, capsules, dry syrups, liquid orals etc. It is currently manufacturing brands like Mox, Cifran, Sporidex, Romilast, Fenak Plus, Omesec-20, Stanhist, Secafe, etc. The company is planning for various international approvals mainly the US FDA and EU MHRA for the Baddi Plant which would help the company to start export business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1752.10 |
| Dr. Reddys Lab | 1339.70 |
| Cipla | 1444.85 |
| Lupin | 2130.00 |
| Zydus Lifesciences | 983.40 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
